MDT|Analyst Targets
MDT|Company Info
MDT|Insider Trading
MDT|Fundamentals
MDT|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'27 | $1.33 | - | - |
| Q1'27 | $1.40 | $1.45 | +3.4% |
| Q4'26 | $1.54 | $1.55 | +0.6% |
| Q3'26 | $1.69 | $1.36 | -19.5% |
| Q3'25 | $1.31 | $1.36 | +3.5% |
| Q2'25 | $1.23 | $1.26 | +2.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'27 | $9.6B | - | - |
| Q1'27 | $9.6B | $9.8B | +1.2% |
| Q4'26 | $9.7B | $9.8B | +0.8% |
| Q3'26 | $9.6B | $9.0B | -6.4% |
| Q3'25 | - | $9.0B | - |
| Q2'25 | - | $8.5B | - |
MDT|Monthly Returns
Market Data
MDT Stock Snapshot
- Market cap
- 117.54B
- P/E ratio
- 22.5
- Day range
- $92.16 – $93.45
- News sentiment
- 54/100 · Neutral
- Analyst target
- $104.44 (+12.3%)
- Consensus
- Buy · 36 analysts
The chart on MDT has not stabilised: price is in the middle of its 52-week range and the trend is still down. Earnings and guidance carry more weight than macro data at this capitalisation.
Reverse DCF
What growth is priced into MDT?
At today's price, Medtronic plc needs to grow free cash flow about 5.1% a year for the next 10 years to justify its valuation at a 6.78% cost of capital. Over its actual history it has compounded free cash flow at 1.6% a year, so the market is asking for 3.5 percentage points above its own delivered rate. On that basis MDT looks priced above what its own growth record supports.
- Implied FCF growth
- 5.1%
- Historical FCF CAGR
- 1.6%
- Growth gap
- +3.5 pts
- Verdict
- RICH
- Discount rate (WACC)
- 6.78%
- Beta
- 0.58
Behaviour On Record
What MDT's own history says about today's numbers
- Realized volatility (21d)
- 24.2% 76th pct
- Below its peak
- -31.0%
- vs 200-day average
- +5.4%
- Up days (1y)
- 47%
Medtronic plc is currently running 24.2% annualised volatility over the last 21 sessions. Measured against MDT's own 13 years of daily returns rather than a market-wide average, that is the 76th percentile — elevated for this stock, against a typical reading of 19.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
MDT is trading -31.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -16.6%, and the deepest was -38.5% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +5.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 63rd percentile — a somewhat wider gap than its own norm. Over the past year MDT closed higher on 47% of sessions, and it is currently 5 sessions into a rising streak.
On October specifically: over 14 years of records, MDT finished the month higher 7 of 14 times, with a median return of -0.0% and an average of +0.3%. Its strongest month historically has been January at +3.1% on average, its weakest September at -2.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: MDT has opened more than 2% away from the prior close in 58 of 3,268 sessions (1.8% of the time), with the largest gaps running +6.3% and -6.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, MDT moved an average of 2.2% in the session after earnings, closing higher 3 of those 3 times, with a median move of +1.6% and a largest of +5.1%.
All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against MDT's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of MDT's sector?
Medtronic plc sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, MDT ranks 3rd of 15 tracked industries, improving.
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 91
- Industry rank
- #3 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on MDT?
BTIG most recently reiterated its rating on Medtronic plc to Buy on Oct 12, 2026 with a price target of $99 (from $100). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- BTIG — Buy
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
Peers & ETF holders
MDT peers & ETF holders
Medical DevicesMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Schonfeld Strategic Advisors LLC | ▲ Buy | 325,270 | 0.03% | $25.45M | 2026-08-14 |
| Ancora Advisors LLC | ▲ Buy | 38,416 | 0.00% | $3.01M | 2026-08-14 |
| Graham Capital Management, L.P. | ▼ Sold out | 0 | 0.00% | $0 | 2026-08-14 |
| Winton Group Ltd | ▼ Sold out | 0 | 0.00% | $0 | 2026-08-07 |
| Brevan Howard Capital Management LP | ▼ Sold out | 0 | 0.00% | $0 | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Kevin Hern | House | OK01 | ▼ Sell | $15K - $50K | 2026-08-24 | 2026-09-01 |
| Richard Dean Dr McCormick | House | GA06 | ▼ Sell | $1K - $15K | 2026-07-30 | 2026-08-14 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2026-05-15 | 2026-06-08 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Kevin Hern | House | OK01 | ▼ Sell | $15K - $50K | 2026-03-20 | 2026-04-03 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-12-18 | 2026-01-15 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-11-13 | 2025-12-11 |
| Richard Dean Dr McCormick | House | GA06 | ▲ Buy | $1K - $15K | 2025-11-05 | 2025-12-09 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-08-14 | 2025-09-11 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-05-15 | 2025-05-31 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-08 | 2025-06-22 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-05-07 | 2026-08-05 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-04-08 | 2025-04-28 |
| George Whitesides | House | CA27 | ▼ Sell | $50K - $100K | 2025-03-24 | 2025-04-23 |
| Bruce Westerman | House | AR04 | ▼ Sell | $1K - $15K | 2025-03-20 | 2025-04-16 |
| Bruce Westerman | House | AR04 | ▲ Buy | $1K - $15K | 2025-03-04 | 2025-04-16 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-02-25 | 2025-03-27 |
| Emily Randall | House | WA06 | ▼ Sell | $1K - $15K | 2025-01-06 | 2025-02-11 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $15K - $50K | 2024-08-26 | 2026-08-05 |
| Shelley Moore Capito | Senate | WV | ▼ Sell | $1K - $15K | 2024-02-09 | 2024-03-15 |
| Pete Ricketts | Senate | NE | ▼ Sell | $50K - $100K | 2023-09-21 | 2023-10-20 |
| Tina Smith | Senate | MN | ▼ Sell | $100K - $250K | 2023-04-05 | 2023-04-19 |
| Richard Dean Dr McCormick | House | GA06 | ▲ Buy | $1K - $15K | 2023-03-15 | 2025-09-17 |
| Dan Sullivan | Senate | AK | ▼ Sell | $1K - $15K | 2022-11-30 | 2023-07-26 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $15K - $50K | 2022-01-21 | 2022-02-14 |